Raymond James & Associates Purchases 4,660 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Raymond James & Associates raised its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 248,348 shares of the medical research company's stock after buying an additional 4,660 shares during the quarter. Raymond James & Associates owned about 0.48% of Charles River Laboratories International worth $67,290,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. IFM Investors Pty Ltd acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth $2,597,000. First Trust Direct Indexing L.P. acquired a new position in Charles River Laboratories International during the first quarter worth about $211,000. Norden Group LLC lifted its holdings in shares of Charles River Laboratories International by 2,642.3% in the first quarter. Norden Group LLC now owns 31,399 shares of the medical research company's stock valued at $8,508,000 after purchasing an additional 30,254 shares in the last quarter. Woodmont Investment Counsel LLC acquired a new stake in shares of Charles River Laboratories International in the first quarter valued at approximately $218,000. Finally, Congress Wealth Management LLC DE increased its stake in shares of Charles River Laboratories International by 0.9% during the 1st quarter. Congress Wealth Management LLC DE now owns 54,316 shares of the medical research company's stock worth $14,717,000 after purchasing an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Analysts Set New Price Targets

CRL has been the subject of a number of analyst reports. Guggenheim cut Charles River Laboratories International from a "buy" rating to a "neutral" rating in a report on Thursday, February 15th. Evercore ISI raised their price target on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an "outperform" rating in a research note on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a "c+" rating to a "b-" rating in a research report on Friday, March 1st. UBS Group upped their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a "buy" rating in a research note on Thursday, February 15th. Finally, Citigroup lifted their target price on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a research note on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $253.23.

Charles River Laboratories International Stock Up 1.6 %

Shares of CRL stock traded up $3.58 during mid-day trading on Friday, reaching $233.47. 466,193 shares of the company were exchanged, compared to its average volume of 482,082. The company has a market capitalization of $12.03 billion, a P/E ratio of 25.35, a P/E/G ratio of 1.80 and a beta of 1.44. The business's 50 day simple moving average is $252.23 and its 200 day simple moving average is $223.97. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.39 by $0.07. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The business's revenue was down 7.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.98 EPS. Research analysts predict that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Victoria L. Creamer sold 5,000 shares of the business's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the sale, the executive vice president now owns 13,550 shares of the company's stock, valued at approximately $3,437,635. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, VP William D. Barbo sold 4,050 shares of the company's stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Victoria L. Creamer sold 5,000 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the sale, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).